The peer-reviewed study, entitled “US Cannabis Laws Projected To Cost Generic And Brand Pharmaceutical Firms Billions”, analyzed how publicly traded pharmaceutical firms fared after adult-use or medical marijuana laws were enacted by states. According to Ziemowit Bednarek, California Polytechnic State University’s Finance Department, together with Sarah Stith, pharmaceutical stocks were worth 1.5-2% lower in only 10 days following cannabis legalization.
Republican Senators James Lankford (Oklahoma) and Pete Ricketts (Nebraska) have introduced a bill that seeks…
New blue hues and flavors from top breeders have arrived. The post New Blueberry weed…
While there are many studies showing potential and promise for using various compounds in cannabis…
Trump's declaration of drug cartels as terrorist organizations and his war cry to ramp up…
A recent poll conducted by the University of Houston’s Hobby School of Public Affairs has…
Candies, Z, OGs, and more from Leafly’s senior editor. The post David Downs’ sickest weed…